Related Experiment Video
Updated: Jul 5, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Current status of clinical trials for glioblastoma
Michael L Salgaller1, Linda M Liau
1Toucan Capital Corp, Bethesda, MD 20814, USA. msalgaller@toucancapital.com
Abstract:
Glioblastoma, the most highly aggressive and lethal form of brain cancer, has been a particular challenge to treat in terms of improving a patient's quality of life and outcome. Each of the current treatment options is limited due to factors intrinsic to the tumor's biology and the special microenvironment of its location within the brain. Surgical resection is limited by the non-circumscribed borders that can be detected. Radiation therapy has to contend with neurotoxicity to adjacent normal tissues. Chemotherapy is constrained by the blood-brain barrier, which is a very real constraint of systemic therapy -- producing minimal benefit with substantial toxicity in order to administer therapeutic dosages. In part, such hurdles explain the reasons why survival has changed little over many decades of research in this field. The newest generation of treatments includes more effective cytotoxic agents, so-called targeted compounds, and biologics/immunotherapeutics. This article summarizes the preclinical proof-of-concept research and human studies involving some of the agents creating the most positive buzz in the medical community. The advantages and limitations of each are described.
Insights
Glioblastoma treatment remains challenging due to tumor biology and brain location. This review covers new targeted and biologic therapies, assessing their potential to improve outcomes for brain cancer patients.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastoma is an aggressive brain cancer with limited treatment options and poor patient outcomes.
- Current therapies like surgery, radiation, and chemotherapy face significant limitations due to tumor characteristics and the brain's microenvironment, including the blood-brain barrier.
- Decades of research have yielded minimal improvements in glioblastoma survival rates.
Purpose of the Study:
- To review and summarize preclinical and clinical research on novel glioblastoma treatment strategies.
- To evaluate the advantages and limitations of emerging targeted compounds and biologics/immunotherapeutics.
- To provide an overview of promising agents generating significant interest in the medical community.
Main Methods:
- Review of preclinical proof-of-concept research.
- Analysis of human studies involving new therapeutic agents.
- Assessment of scientific literature on targeted compounds and biologics/immunotherapeutics for glioblastoma.
Main Results:
- Identified several novel cytotoxic agents, targeted compounds, and biologics/immunotherapeutics showing promise.
- Detailed the specific advantages and limitations associated with each class of emerging treatment.
- Highlighted agents with significant positive preclinical and early clinical data.
Conclusions:
- Newer therapeutic modalities, including targeted therapies and immunotherapies, offer potential advancements in glioblastoma treatment.
- Despite promise, challenges related to tumor biology and delivery persist.
- Further research and clinical evaluation are crucial to overcome existing hurdles and improve patient survival and quality of life.
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...